PRMT5 and pancreatic neoplasm: Moreover, the same inhibitor also demonstrated that inhibition of PRMT5 significantly reduced gemcitabine resistance in pancreatic cancer caused by UBR7 depletion (Table 4) (Bi et al., 2023).